



Minerva Access is the Institutional Repository of The University of Melbourne

**Author/s:**

Doolan, BJ;Robinson, AJ;Regan, M;Ragunathan, A;Winship, I

**Title:**

Genetic mosaicism in dermatology: Clinical utility of genetic testing of skin lesions

**Date:**

2020-02-01

**Citation:**

Doolan, B. J., Robinson, A. J., Regan, M., Ragunathan, A. & Winship, I. (2020). Genetic mosaicism in dermatology: Clinical utility of genetic testing of skin lesions. *Australasian Journal of Dermatology*, 61 (1), pp.92-94. <https://doi.org/10.1111/ajd.13149>.

**Persistent Link:**

<https://hdl.handle.net/11343/286336>

## TITLE PAGE

**Article Title:**

Genetic mosaicism in dermatology: Clinical utility of genetic testing of skin lesions

*Running Head: Genetic mosaicism in dermatology*

**Author Information: (Correspondence via Brent Doolan)**

Brent J Doolan, BSc MBBS MPH&TM

Department of Genomic Medicine

Department of Dermatology

The Royal Melbourne Hospital, Melbourne, Victoria, Australia 3050

Ph: +61 3 9342 7151

E: [brent.doolan@mh.org.au](mailto:brent.doolan@mh.org.au)

Aaron J Robinson, BBiotech(Hons) MBBS PhD

Department of Dermatology

The Royal Melbourne Hospital

Ph: +61 3 9342 4531

E: [aaronjamesrobinson@gmail.com](mailto:aaronjamesrobinson@gmail.com)

Matthew Regan, MBBS PhD FRACP

Department of General Genetics

Monash Health, Monash Medical Centre, Melbourne, Victoria, Australia 3168

Ph: +61 3 9594 2026

E: [matthew.regan@monashhealth.org](mailto:matthew.regan@monashhealth.org)

Abiramy Rangunathan, BSc(Med) MBBS(Hons) FRACP

Familial Cancer Services, The Crown Princess Mary Cancer Centre

Westmead Hospital, Westmead, NSW, Australia 2145

Ph: +61 2 8890 5200

E: [abiramy.rangunathan@health.nsw.gov.au](mailto:abiramy.rangunathan@health.nsw.gov.au)

Ingrid Winship, MBChB MD FACD FRACP

**This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as [doi: 10.1111/AJD.13149](https://doi.org/10.1111/AJD.13149)**

This article is protected by copyright. All rights reserved

Department of Genomic Medicine

The Royal Melbourne Hospital, Melbourne, Victoria, Australia 3050

Department of Medicine

The University of Melbourne, Melbourne, Victoria, Australia 3010

Ph: +61 3 9342 7151

E: ingrid.winship@mh.org.au

***Conflicts of Interest/Disclosures:***

The authors declare that they have no financial or other conflicts of interest in relation to this research and its publication. There was no funding supplied from any source.

**Word count:** 749

**References:** 8

**Figures:** 3

Article type : Research Letter

**MANUSCRIPT:**

***Genetic mosaicism in dermatology: Clinical utility of genetic testing of skin lesions***

Mosaicism is defined as the existence of two or more distinct clonal cell populations within one individual, which is the product of a single fertilised egg.<sup>1</sup> Mosaicism is an acquired mutation during embryonic development and can be classified according to reproductive risk: *somatic* mosaicism is limited to non-reproductive cells; *gonadal* mosaicism is found only in reproductive cells and can be expressed constitutionally in future generations and *gonosomal* mosaicism is in both.<sup>1,2</sup> Mosaic presentations of genetic disorders are often observable in a segmental form in the skin, due to postzygotic *de novo* mutations.<sup>1</sup> Thus, cutaneous mosaic disorders offer a unique opportunity to investigate genetic mosaicism.

Genetic investigation has been enhanced by next generation sequencing, which sequences nucleotides faster and cheaper than traditional Sanger sequencing.<sup>3</sup> Mosaicism can be determined by testing constitutional DNA from peripheral blood lymphocytes and comparing to somatic DNA derived from a biopsy of affected skin. The clinical value of confirming somatic mosaicism is twofold; it may infer prognosis or outcome, whilst potentially providing a risk assessment to future offspring. We illustrate the clinical utility of genetic testing in suspected mosaicism, presenting a case series of patients seen in the multidisciplinary Genodermatoses Clinic at the Royal Melbourne Hospital.

*Case 1: Proteus Syndrome*

A 47-year-old female was noted at 12-months of age to have hypertrophy of the right thumb and index finger (Fig. 1). A clinical diagnosis of Proteus Syndrome was made, before

genetic testing was feasible. She later developed epidermal naevi on her chest and right leg. DNA extracted from a naevus biopsy exhibited a pathogenic missense variant, *AKT1* c.49G>A(p.Glu17Lys). This variant which was absent from peripheral blood DNA, confirmed a diagnosis of Proteus syndrome with segmental overgrowth due to activation of the PI3K/AKT/mTOR pathway.<sup>4</sup> The variant causes an increased risk of meningiomas and reproductive malignancies.<sup>4,5</sup>

#### *Case 2: Segmental Darier Disease*

A 35-year-old man had a 15-month history of keratotic papules across his left chest and flank in a Blaschkoid distribution. Histopathology showed focal acantholytic dyskeratosis, clinically consistent with a diagnosis of segmental Darier disease. He sought reproductive advice given his diagnosis. The c.2249G>A(p.Arg750Gln) variant was found in the *ATP2A2* gene in the skin biopsy, but not peripheral blood, suggesting a likely pathogenic R750Q mosaic variant.<sup>6</sup> While there is a low likelihood that he will produce offspring with Darier disease, he was counselled regarding his option of prenatal testing or preimplantation genetic diagnosis because of the location of his lesions.

#### *Case 3: Epidermal naevus*

A 37-year-old female had keratinocytic epidermal naevi in a Blaschkoid distribution over her left shoulder and mid-back (Fig. 2). The naevi were present from birth. She was undergoing *in vitro fertilisation* pregnancy. Given the concern of systematisation in her future children, she was considering preimplantation genetic diagnosis, if genetic testing confirmed a germline mutation. A heterozygous pathogenic variant c.742C>T(p.Arg248Cys) of the *FGFR3* gene was found in affected skin, but not in peripheral blood; indicating a *de novo* somatic mutation. Genetic counselling was provided and given the low likelihood of inheritance, preimplantation genetic diagnosis was not requested.

#### *Case 4: Segmental Neurofibromatosis Type 1*

A 38-year-old male sought advice following a clinical diagnosis of Neurofibromatosis Type 1 in his infant son, confirmed by the NF1:c.1756\_1759del pathogenic variant. Examination of the patient revealed café au lait macules in a Blaschkoid distribution overlying his left lower abdomen, raising the possibility of segmental Neurofibromatosis Type 1 affecting gonadal tissue (Fig. 3). DNA testing of peripheral blood and lesional skin did not reveal the mutation evident in his son's DNA. Genetic counselling includes a potential risk of 50:50 to future children.<sup>5</sup>

*Case 5 and 6(Published):*

Case 5 demonstrated phacomatosis pigmentokeratocica with a pathogenic heterozygous variant in the *HRAS* gene,c.37G>C(p.Gly13Arg) in DNA extracted from a sebaceous naevus of a 22-year-old male.<sup>7</sup> Case 6 demonstrated X-linked dominant chondrodysplasia punctata(CDPX2) with a post-zygotic variant in the *EBP* gene,c.10\_20del(p.Asn4fs) of a 25-year-old male, with longstanding cicatricial alopecia and Blaschkoid ichthyosis.<sup>8</sup>

Mosaicism of single gene disorders explains segmental skin lesions in a range of heritable skin disorders. A mutation was identified in DNA derived from skin biopsies, which was not present in peripheral blood DNA in five of these six cases. Where lesional skin was in close proximity to gonadal tissue, patients were counselled to the possibility of gonadal mosaicism.<sup>5</sup> In cases of mosaicism not involving gonadal tissue, it is reasonable to reassure the patients that the likelihood of disease being passed on to offspring is low. We validate the clinical utility of genetic testing, and the unique opportunity it provides to diagnose and manage potential risks associated with somatic mosaicism.

**ACKNOWLEDGMENTS:**

None.

**REFERENCES:**

1. Vreeburg M, van Steensel MA. Genodermatoses caused by genetic mosaicism. *Eur. J. Pediatr.* 2012; 171(12): 1725-35. doi: 10.1007/s00431-012-1855-9.
2. Lim YH, Moscato Z, Choate KA. Mosaicism in cutaneous disorders. *Annu. Rev. Genet.* 2017; 51: 123-41. doi: 10.1146/annurev-genet-121415-121955.
3. Park St, Kim J. Trends in next-generation sequencing and a new era for whole genome sequencing. *Int. Neurol. J.* 2016; 20(Suppl 2): S76-83. doi: 10.5213/inj.1632742.371.
4. Lindhurst MJ, Sapp JC, Teer JK et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. *N. Engl. J. Med.* 2011; 365(7): 611-19. doi: 10.1056/NEJMoa1104017.
5. Kinsler VA, Boccara O, Freitag S et al. Mosaic abnormalities of the skin - review and guidelines from the European Reference Network for rare skin diseases (ERN-Skin). *Br. J. Dermatol.* 2019 Mar 28. doi: 10.1111/bjd.17924.
6. Green EK, Gordon-Smith K, Burge SM et al. Novel ATP2A2 mutations in a large sample of individuals with Darier disease. *J. Dermatol.* 2013; 40(4): 259-66. doi: 10.1111/1346-8138.12082.
7. Cranwell WC, Walsh M, Winship I. Phacomatosis pigmentokeratotic: Postzygotic HRAS mutation with malignant degeneration of the sebaceous naevus. *Australas. J. Dermatol.* 2019 Feb 14. doi: 10.1111/ajd.13007.
8. Honigman A, De Cruz R, Sinclair R, Winship I. Chondrodysplasia punctata (CDPX2) in a male caused by single-gene mosaicism: A 20-year follow-up. *Australas. J. Dermatol.* 2019; 60(2): e160-e162. doi: 10.1111/ajd.12938.

#### FIGURE LEGENDS:

**Figure 1:** Asymmetric and disproportionate over growth of right-hand fingers with macrodactyly in a 47-year-old female with Proteus syndrome.

**Figure 2:** **A.** Scattered epidermal naevi located over the left chest, shoulder and **B.** lower back of a 37-year-old female with somatic epidermal naevi.

**Figure 3: A.** A streak of café au lait macules overlying the left lower abdomen in a 38-year-old male, raising the possibility of segmental Neurofibromatosis Type 1. **B.** Magnified image of left lower abdomen showing scattered macules in a linear, Blaschkoid pattern.

Author Manuscript



ajd\_13149\_f1.jpg



ajd\_13149\_f2.jpg

Author Manuscript



ajd\_13149\_f3.jpg

Author Manuscript